ArticleThe Journal of antimicrobial chemotherapy2014
Liposomal resiquimod for the treatment of Leishmania donovani infection.
Article in The Journal of antimicrobial chemotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 45 citations in OpenAlex.
- Gardiquimod Nanoemulsion Targets Cutaneous Leishmaniasis Lesions Reducing Systemic Toxicity and Parasite Burden.Advanced healthcare materials · 2026Article
- Protective immune response induced by cationic liposomes bearing soluble antigens improves the survival of BALB/c mice againstIranian journal of basic medical sciences · 2025Article
- The Use of an Adjuvant System Improves Innate and Adaptive Immune Response When Associated with aVaccines · 2023Article
- Immunotherapy and immunochemotherapy in combating visceral leishmaniasis.Frontiers in medicine · 2023Review
- Liposomal drug delivery systems for the treatment of leishmaniasis.Parasitology research · 2022Review
- Nanocarriers for effective delivery: modulation of innate immunity for the management of infections and the associated complications.Journal of nanobiotechnology · 2022Review
- A Squalene-Based Nanoemulsion for Therapeutic Delivery of Resiquimod.Pharmaceutics · 2021Article
- Nano- and Microformulations to Advance Therapies for Visceral Leishmaniasis.ACS biomaterials science & engineering · 2021Review
- Development of thermosensitive resiquimod-loaded liposomes for enhanced cancer immunotherapy.Journal of controlled release : official journal of the Controlled Release Society · 2021Article
- Polyphosphazene immunoadjuvants: Historical perspective and recent advances.Journal of controlled release : official journal of the Controlled Release Society · 2021Review
- High-capacity poly(2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of lung adenocarcinoma.Science advances · 2020Article
- Supramolecular assembly of Toll-like receptor 7/8 agonist into multimeric water-soluble constructs enables superior immune stimulationACS applied bio materials · 2020Article
- Envisioning the innovations in nanomedicine to combat visceral leishmaniasis: for future theranostic application.Nanomedicine (London, England) · 2019Review
- Nanoparticle Vaccines Adopting Virus-like Features for Enhanced Immune Potentiation.Nanotheranostics · 2017Review
- Antileishmanial and Cytotoxic Activity of Some Highly Oxidized Abietane Diterpenoids from the Bald Cypress, Taxodium distichum.Journal of natural products · 2016Article
- Host-mediated Leishmania donovani treatment using AR-12 encapsulated in acetalated dextran microparticles.International journal of pharmaceutics · 2016Article
- One Step Encapsulation of Small Molecule Drugs in Liposomes via Electrospray-Remote Loading.Molecular pharmaceutics · 2016Article
- Northalrugosidine is a bisbenzyltetrahydroisoquinoline alkaloid from Thalictrum alpinum with in vivo antileishmanial activity.Journal of natural products · 2015Article
- Topical resiquimod protects against visceral infection with Leishmania infantum chagasi in mice.Clinical and vaccine immunology : CVI · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
objectivesThe imidazoquinoline family of drugs are Toll-like receptor 7/8 agonists that have previously been used in the treatment of cutaneous leishmaniasis. Because of the hydrophobic nature of imidazoquinolines, they are traditionally not administered systemically for the treatment of visceral leishmaniasis. We formulated liposomal resiquimod, an imidazoquinoline, for the systemic treatment of visceral leishmaniasis.
methodsBy using lipid film hydration with extrusion, we encapsulated resiquimod in liposomes. These liposomes were then injected intravenously to treat BALB/c mice infected with Leishmania donovani.
resultsTreatment with liposomal resiquimod significantly decreased the parasite load in the liver, spleen and bone marrow. In addition, resiquimod treatment increased interferon-γ and interleukin-10 production in an antigen recall assay. Resiquimod was shown to be non-toxic in histology and in vitro culture experiments.
conclusionsFDA-approved resiquimod, in a liposomal formulation, displays promising results in treating visceral leishmaniasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.